Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase, or subscribe for securities of the Company.

友芝友生物製藥

WUHAN YZY BIOPHARMA CO., LTD.
武漢友芝友生物製藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2496)

ANNOUNCEMENT
DESPATCH OF CIRCULAR IN RELATION TO
(1) CONNECTED TRANSACTION IN RESPECT OF THE PROPOSED ISSUE OF NEW DOMESTIC SHARES UNDER SPECIFIC MANDATE;
(2) APPLICATION FOR WHITEWASH WAIVER; AND
(3) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Reference is made to the circular of Wuhan YZY Biopharma Co., Ltd. (the "**Company**") dated 30 October 2026 (the "**Circular**") in relation to, among other things, the Share Subscription, the Specific Mandate, the Whitewash Waiver and the proposed amendments to the Articles. Unless otherwise defined, capitalised terms used in this announcement have the same meanings as those defined in the Circular.

The Company is pleased to announce that the Circular containing, among other things, (i) details of the Share Subscription, the Specific Mandate, the Whitewash Waiver and the proposed amendments to the Articles; (ii) a letter of recommendation from the Connected Transaction IBC to the Independent Shareholders on the Share Subscription and the Specific Mandate; (iii) a letter of recommendation from the Whitewash Waiver IBC to the Independent Shareholders on the Share Subscription, the Specific Mandate and the Whitewash Waiver; (iv) a letter of advice by the Independent Financial Adviser to the Independent Board Committees and the Independent Shareholders on the Share Subscription, the Specific Mandate and the Whitewash Waiver; and (v) a notice of EGM together with the form of proxy, has been despatched to the Shareholders on 30 October 2026.

The EGM will be held on Tuesday, 17 November 2026 at 10:00 a.m. at Conference Room 3, 2nd Floor, Building C2–1, No. 666 Gaoxin Road, East Lake High Tech Development Zone, Wuhan, Hubei Province, PRC.

Shareholders and potential investors of the Company are advised to note that, as the Share Subscription is subject to the satisfaction of the Conditions Precedent, including but not limited to the granting of the Whitewash Waiver by the Executive and the approval of the Share Subscription and the Whitewash Waiver by Independent Shareholders, the proposed Share Subscription may or may not proceed. Therefore, Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company and are recommended to consult their stockbroker, bank manager, solicitor or other professional adviser if they are in any doubt about their position and as to actions that they should take.

By order of the Board
Wuhan YZY Biopharma Co., Ltd.
Dr. Zhou Pengfei
Chairman of the Board,
Executive Director and Chief Executive Officer

Wuhan, PRC, 3 November 2026

As at the date of this announcement, the Board comprises Dr. Zhou Pengfei and Mr. Wen Zhicheng as executive Directors; Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu and Mr. Xie Shouwu as non-executive Directors; and Dr. Cheng Bin, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive Directors.

All the Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.